IRADIMED Yönetim

Yönetim kriter kontrolleri 4/4

IRADIMED CEO'su Roger Susi, Jan2004 tarihinde atandı, in görev süresi 20.83 yıldır. in toplam yıllık tazminatı $ 642.57K olup, şirket hissesi ve opsiyonları dahil olmak üzere 47.9% maaş ve 52.1% ikramiyelerden oluşmaktadır. şirketin hisselerinin 36.2% ine doğrudan sahiptir ve bu hisseler € 232.98M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.3 yıl ve 8.4 yıldır.

Anahtar bilgiler

Roger Susi

İcra Kurulu Başkanı

US$642.6k

Toplam tazminat

CEO maaş yüzdesi	47.9%
CEO görev süresi	20.8yrs
CEO sahipliği	36.2%
Yönetim ortalama görev süresi	3.3yrs
Yönetim Kurulu ortalama görev süresi	8.4yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Roger Susi'un ücretlendirmesi IRADIMED'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	US$19m
Jun 30 2024	n/a	n/a	US$19m
Mar 31 2024	n/a	n/a	US$18m
Dec 31 2023	US$643k	US$308k	US$17m
Sep 30 2023	n/a	n/a	US$16m
Jun 30 2023	n/a	n/a	US$15m
Mar 31 2023	n/a	n/a	US$14m
Dec 31 2022	US$586k	US$290k	US$13m
Sep 30 2022	n/a	n/a	US$13m
Jun 30 2022	n/a	n/a	US$12m
Mar 31 2022	n/a	n/a	US$10m
Dec 31 2021	US$615k	US$308k	US$9m
Sep 30 2021	n/a	n/a	US$6m
Jun 30 2021	n/a	n/a	US$5m
Mar 31 2021	n/a	n/a	US$987k
Dec 31 2020	US$435k	US$290k	US$1m
Sep 30 2020	n/a	n/a	US$4m
Jun 30 2020	n/a	n/a	US$5m
Mar 31 2020	n/a	n/a	US$10m
Dec 31 2019	US$488k	US$288k	US$10m
Sep 30 2019	n/a	n/a	US$8m
Jun 30 2019	n/a	n/a	US$8m
Mar 31 2019	n/a	n/a	US$7m
Dec 31 2018	US$495k	US$279k	US$6m
Sep 30 2018	n/a	n/a	US$5m
Jun 30 2018	n/a	n/a	US$3m
Mar 31 2018	n/a	n/a	US$2m
Dec 31 2017	US$474k	US$268k	US$500k

Tazminat ve Piyasa: Roger 'nin toplam tazminatı ($USD 642.57K ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 1.46M ).

Tazminat ve Kazançlar: Roger 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Roger Susi (71 yo)

20.8yrs

Görev süresi

US$642,566

Tazminat

Mr. Roger E. Susi serves as President and Chief Executive Officer of IRadimed Corporation since May 28, 2020. He founded IRadimed Corporation in 2004 and has been its Chairman of the Board since June 10, 2...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Roger Susi	Founder	20.8yrs	US$642.57k	36.2% € 233.0m
John Glenn	CFO & Corporate Secretary	2.4yrs	US$1.27m	0.054% € 349.5k
Randy Waddell	Vice President of Worldwide Sales & Marketing	3.3yrs	US$597.28k	0.047% € 303.7k
Chris Williamson	Executive Vice President of Continuous Improvement & Information Technology	2.4yrs	Veri yok	Veri yok
Matt Garner	Controller	4.8yrs	Veri yok	Veri yok
Steve Kachelmeyer	Vice President of Regulatory Affairs & Quality Assurance	no data	US$425.08k	0.042% € 267.9k
Lynn Neuhardt	Vice President of Research & Development	no data	US$442.20k	0.050% € 322.5k

3.3yrs

Ortalama Görev Süresi

Deneyimli Yönetim: 46K 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Roger Susi	Founder	8.4yrs	US$642.57k	36.2% € 233.0m
James Hawkins	Director	5.4yrs	US$159.36k	0.31% € 2.0m
Anthony Vuoto	Independent Director	8.7yrs	US$167.48k	0.11% € 722.8k
Monty Allen	Independent Director	10.8yrs	US$169.98k	0.14% € 916.8k
Hilda Scharen-Guivel	Independent Director	2.1yrs	US$153.11k	0.028% € 179.4k

8.4yrs

Ortalama Görev Süresi

71yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 46K 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.4 yıldır).

IRADIMED Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Independent Director recently sold €78k worth of stock

IRADIMED CORPORATION, Annual General Meeting, Jun 20, 2024

IRadimed Corporation Announces Board Changes

Independent Director recently sold €113k worth of stock

Insufficient new directors

Insufficient new directors

Recent updates

Upcoming dividend of US$0.15 per share

Investor sentiment improves as stock rises 27%

Third quarter 2024 earnings released: EPS: US$0.40 (vs US$0.40 in 3Q 2023)

Iradimed Corporation Revises Earnings Guidance for the Year 2024

IRADIMED CORPORATION to Report Q3, 2024 Results on Oct 31, 2024

Upcoming dividend of US$0.15 per share

Second quarter 2024 earnings released: EPS: US$0.39 (vs US$0.33 in 2Q 2023)

IRADIMED CORPORATION Declares A Regular Quarterly Cash Dividend, Payable on August 30, 2024

IRADIMED CORPORATION to Report Q2, 2024 Results on Aug 01, 2024

Independent Director recently sold €78k worth of stock

IRADIMED CORPORATION Declares Regular Quarterly Cash Dividend, Payable on May 30, 2024

IRADIMED CORPORATION, Annual General Meeting, Jun 20, 2024

IRADIMED CORPORATION to Report Q1, 2024 Results on May 02, 2024

Full year 2023 earnings released: EPS: US$1.36 (vs US$1.02 in FY 2022)

IRadimed Corporation Provides Revenue Guidance for the First Quarter and Full Year of 2024

IRadimed Corporation to Report Q4, 2023 Results on Feb 08, 2024

IRadimed Corporation Approves Special Cash Dividend, Payable on January 12, 2024

Iradimed Corporation Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

IRadimed Corporation to Report Q3, 2023 Results on Nov 03, 2023

IRadimed Corporation Provides Earnings Guidance for the Third Quarter and for the Full Year of 2023

IRadimed Corporation to Report Q2, 2023 Results on Aug 03, 2023

IRadimed Corporation Revises Earnings Guidance for the Year 2023

Investor sentiment improves as stock rises 32%

Full year 2022 earnings released: EPS: US$1.02 (vs US$0.76 in FY 2021)

Iradimed Corporation Approves Special Cash Dividend, Payable on February 21, 2023

IRadimed Corporation to Report Q4, 2022 Results on Feb 02, 2023

IRadimed Corporation Provides Earnings Guidance for the First Quarter of 2023 and Full Year 2023

Iradimed Corporation Provides Revenue Guidance for the Fourth Quarter and Full Year 2022

IRadimed Corporation to Report Q3, 2022 Results on Nov 03, 2022

IRadimed Corporation Provides Revenue Guidance for the Third Quarter Ended September 30, 2022

IRadimed Corporation Announces Board Changes

Independent Director recently sold €113k worth of stock

Insufficient new directors

Iradimed Corporation Revises Earnings Guidance for the Full Year 2022

Second quarter 2022 earnings released: EPS: US$0.26 (vs US$0.12 in 2Q 2021)

IRadimed Corporation to Report Q2, 2022 Results on Jul 29, 2022

Insufficient new directors

IRadimed Corporation Names John F. Glenn as Chief Financial Officer, Effective on or before June 20, 2022

Iradimed Corporation Revises Earnings Guidance for the Full Year 2022

IRadimed Corporation to Report Q1, 2022 Results on Apr 29, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

IRadimed Corporation Announces Special Share Cash Dividend, Payable on February 24, 2022

iRadimed Corporation Provides Earnings Guidance for the First Quarter and Full Year of 2022

Independent Director recently sold €785k worth of stock

Second quarter 2021 earnings released: EPS US$0.12 (vs US$0.17 loss in 2Q 2020)

First quarter 2021 earnings released: EPS US$0.11 (vs US$0.15 in 1Q 2020)

IRadimed Corporation Provides Financial Guidance for Fiscal Year 2021

Full year 2020 earnings released

Revenue beats expectations

New 90-day high: €20.80

IRadimed Corporation to Report Q4, 2020 Results on Feb 04, 2021

New 90-day high: €19.70

Third quarter 2020 earnings released: EPS US$0.088

Revenue beats expectations

Third quarter earnings released

Third-quarter earnings released: Revenue beats expectations

IRadimed Corporation to Report Q3, 2020 Results on Oct 30, 2020

IRadimed Corporation Withdraws Full-Year 2020 Financial Guidance and Not Providing Any Additional Financial Guidance

IRadimed Corporation to Report Q2, 2020 Results on Jul 30, 2020

IRadimed Corporation(NasdaqCM:IRMD) dropped from Russell 2000 Dynamic Index

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş